Transgenic Mouse Models in Cancer Research.

Area of Science:

• Oncology
• Translational Medicine
• Genetics

Background:

• Mouse models are vital for cancer research, but limitations in reflecting human tumor complexity hinder clinical translation.
• Traditional models include syngeneic and xenografted tumors, alongside transgenic mice for gene manipulation.
• Existing models face challenges in accurately mimicking human tumor heterogeneity and the tumor microenvironment.

Purpose of the Study:

• To review the evolution and impact of mouse cancer models in oncology research.
• To highlight the advantages of novel mouse models in studying carcinogenesis and therapy resistance.
• To emphasize the role of advanced models in developing precise, individualized cancer therapies.

Main Methods:

• Utilizing clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 for advanced genome editing in mouse models.
• Developing humanized mouse xenograft models with patient-derived xenografts and CD34+ cells.
• Comparing traditional mouse models (syngeneic, xenograft, transgenic) with newer engineered systems.

Main Results:

• CRISPR/Cas9 technology enables engineering of diverse mutations found in human cancers, overcoming previous limitations.
• Humanized xenograft models better mimic tumor heterogeneity, microenvironment, and cell interactions, crucial for immunotherapy evaluation.
• Improvements in mouse models enhance their validity and ability to represent complex human cancer biology.

Conclusions:

• Enhanced mouse models, particularly CRISPR/Cas9-based and humanized xenografts, are pivotal for advancing cancer research.
• These sophisticated models facilitate a deeper understanding of tumor biology and therapeutic responses.
• The development of more accurate mouse models paves the way for precise, individualized cancer therapies, improving patient outcomes.